Diuretics in chronic heart failure - Benefits and hazards

European Heart Journal, Supplement

Volumn 3, Issue G, 2001, Pages

  Anand, I S ^a   Florea, V G ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Arrhythmia; Diuretics; Electrolyte disturbances; Heart failure; Prognosis; Torasemide

Indexed keywords

DIURETIC AGENT; SPIRONOLACTONE;

BLOOD PRESSURE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; EDEMA; ELECTROLYTE DISTURBANCE; FLUID RETENTION; HEART ARRHYTHMIA; HEART PERFORMANCE; HEART STROKE VOLUME; HORMONE ACTION; HUMAN; HYPERTENSION; METABOLISM; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0034890206     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (130)

1. National Ambulatory Medical Care Survey: 1991 Summary
2. Hemodynamic effects of diuresis at rest and during intense upright exercise in patients with impaired cardiac function
3. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics
4. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
5. Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure
6. Effect of acute diuresis on aldosterone secretion in edematous patients
7. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men
8. Diuretic-induced hypokalemia in uncomplicated systemic hypertension: Effect of plasma potassium correction on cardiac arrhythmias
9. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction
10. Effect of furosemide on hemodynamics and lung water in acute pulmonary edema secondary to myocardial infarction
11. Hemodynamic effects of massive peripheral edema
12. Diuretics as initial and sole treatment in chronic cardiac failure
13. Effect of diuresis on the performance of the failing left ventricle in man
14. Origins of symptoms in heart failure
15. Controlled, double-blind clinical trial on the efficacy and tolerance of torasemide in comparison with furosemide in patients with congestive heart failure - A multicenter study
16. Long-term efficacy and tolerance of torasemide in congestive heart failure
17. Muzolimine as monotherapy in the treatment of patients with congestive cardiac failure
18. Central hemodynamic effects of diuretic therapy in chronic heart failure
19. Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide
20. Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide
21. Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity
22. Diuretics
23. The role of furosemide alone and in combination with digoxin in the relief of symptoms of congestive heart failure
24. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure
25. Der einfluss von piretanid auf die zentrale hämodynamik und belastungstoleranz von patienten mit angina pectoris
26. Hemodynamic effects of diuresis by ethacrynic acid in normal subjects and in patients with congestive heart failure
27. Diuretics in the prevention and treatment of congestive heart failure
28. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure
29. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy
30. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
31. Aldosterone and antialdosterone therapy in congestive heart failure
32. Aldosterone and heart failure
33. Pathological hypertrophy and cardiac interstitium. Fibrosis and rennin-angiotensin-aldosterone system
34. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
35. Effects of type of diuretic on mortality in patients with chronic congestive heart failure
36. Neurohormonal influences in the pathogenesis of congestive heart failure
37. Diuretic treatment for the sodium retention of congestive heart failure
38. Mechanisms and management of renal dysfunction in heart failure
39. Aldosterone and its regulation during diuresis in patients with gross congestive heart failure
40. Relation of plasma aldosterone concentration to diuretic treatment in patients with severe heart disease
41. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure
42. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure
43. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality
44. Neuorhormonal responses in congestive heart failure: Effect of ACE inhibitors in randomized controlled clinical trials
45. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery
46. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy
47. The neurohumoral axis in congestive heart failure
48. Oedema and decreased renal blood flow in patients with chronic congestive heart failure - Evidence of 'forward failure' as the primary cause of oedema
49. The pharmacologic alteration of renin release
50. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure
51. Pathogenesis of edema in constrictive pericarditis. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones before and after pericardiectomy
52. Neuroendocrine response in acute heart failure and the influence of treatment
53. Sodium and water balance in chronic congestive heart failure
54. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics
55. Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: Relation to adenylate cyclase activation
56. Human plasma vasopressin response to potent loop-diuretic drugs
57. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohormonal axis
58. Neurohormonal modulation in chronic heart failure
59. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
60. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure
61. Pathogenesis of salt and water retention in the congestive heart failure syndrome
62. Hemodynamic, hormonal, and renal effects of atrial natriuretic peptide in untreated congestive cardiac failure
63. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion
64. Diuretics: Clinical pharmacology and therapeutic use (part 1)
65. Diuretics: Clinical pharmacology and therapeutic use (part 2)
66. Diuretics and other agents employed in the mobilization of edema fluid
67. Plasma and skeletal muscle electrolytes in patients on long-term diuretic therapy for arterial hypertension and/or congestive heart failure
68. Approaches to diuretic therapy and electrolyte imbalance in congestive heart failure
69. 2+, and Cl
70. Electrolyte disarray and cardiovascular disease
71. Provocation of hyper- and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure
72. Importance of magnesium in congestive heart failure
73. Magnesium content of serum, circulating mononuclear cells, skeletal muscle, and myocardium in congestive heart failure
74. Influence of chronic diuretic therapy on serum, lymphocyte and erythroctye potassium, magnesium and calcium concentrations
75. Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics
76. Magnesium deficiency in patients on long-term diuretic therapy for heart failure
77. Acute changes in plasma renin activity, plasma aldosterone concentration and plasma electrolyte concentrations following furosemide administration in patients with congestion heart failure - Interrelationships and diuretic response
78. Diuretic-associated hypomagnesemia
79. Magnesium in heart muscle
80. Magnesium deficiency and distribution of blood in the rat
81. Torsade de pointes and magnesium deficiency
82. Prognostic importance of the serum magnesium concentration in patients with congestive heart failure
83. Serum and tissue magnesium concentrations in patients with heart failure and serious ventricular arrhythmias
84. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
85. Association of hyponatremia with increased renin activity in chronic congestive heart failure: Impact of diuretic therapy
86. Profound hyponatremia resulting from a thiazide-induced decrease in urinary diluting capacity in a patient with primary polydipsia
87. Osmotic and nonosmotic control of vasopressin release
88. Correction of dilutional hyponatremia in severe chronic heart failure by convertingenzyme inhibition
89. Renal response to captopril in severe heart failure: Role of furosemide in natriuresis and reversal of hyponatremia
90. The role of volume contraction in the hypocalciuric action of chlorothiazide
91. The efficacy and safety of diuretics in treating hypertension
92. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality result
93. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial
94. Diuretic therapy for hypertension and the risk of primary cardiac arrest
95. Diuretic therapy, hypertension, and cardiac arrest
96. Potassium and magnesium abnormalities: Diuretics and arrhythmias in hypertension
97. Diuretic-induced ventricular ectopic activity
98. Thiazide diuretics, hypokalemia and cardiac arrhythmias
99. How dangerous are diuretics?
100. Potassium loss, ventricular irritability, and the risk of sudden death in hypertensive patients
101. Diuretics, hypokalaemia and arrhythmias in hypertensive patients: Still an unresolved problem
102. Cardiotoxicity and diuretics: Much speculation - Little substance
103. Sudden cardiac death in patients with hypertension. An association with diuretics and beta-blockers?
104. Effect of antihypertensive treatment on stroke recurrence
105. MRC trial of treatment of mild hypertension: Principal results
106. Treatment of mild hypertension: A five year controlled drug trial. The Oslo study
107. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program
108. Treatment of mild hypertension: Results of a ten-year intervention trial
109. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg
110. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
111. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: Hyponatremia, hypokalemia, and hypomagnesemia
112. Absorption and disposition of furosemide in congestive heart failure
113. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation
114. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion
115. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure
116. + transport
117. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment
118. Adaptation of distal convoluted tubule of rats. II. Effects of chronic thiazide infusion
119. The effect of chronic hydrochlorothiazide administration on renal function in the rat
120. Comparison of captopril and enalapril in patients with severe chronic heart failure
121. Restoration of renal response to atrial natriuretic factor in experimental low-output heart failure
122. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure
123. Variable furosemide absorption and poor predictability of response in elderly patients
124. Anti-aldosteronergic effect of torasemide
125. Torasemide versus furosemide in patients with congestive heart failure: A double-masked, randomised study
126. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers
127. Pathophysiology of furosemide ototoxicity
128. Permanent deafness associated with furosemide administration
129. Combinations of diuretics in the treatment of edema
130. Treatment of edema by the combined use of chemically different diuretic agents